 | • レポートコード：MRC2303B015 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の多血小板血漿（PRP）市場規模が予測期間中（2022～2027年）に年平均12.4％上昇すると推測されています。本調査書では、多血小板血漿（PRP）の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（ピュアPRP、白血球含有多型PRP、白血球含有多型フィブリン）分析、エンドユーザー別（病院・診療所、研究機関）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Arthrex Inc.、Isto Biologics、Vertical Spine LLC、DePuy Synthes、Dr. PRP USA LLC、EmCyte Corporation、Glofinn Oy、T-Biotechnology、Terumo BCT Inc.、Zimmer Biomet、Harvest Technologies Corporation、ISTO Biologicsなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の多血小板血漿（PRP）市場規模：種類別 - ピュアPRPの市場規模 - 白血球含有多型PRPの市場規模 - 白血球含有多型フィブリンの市場規模 - その他多血小板血漿（PRP）の市場規模 ・世界の多血小板血漿（PRP）市場規模：用途別 - 整形外科における市場規模 - 美容外科・皮膚科における市場規模 - 神経内科における市場規模 - 循環器内科における市場規模 - その他用途における市場規模 ・世界の多血小板血漿（PRP）市場規模：エンドユーザー別 - 病院・診療所における市場規模 - 研究機関における市場規模 ・世界の多血小板血漿（PRP）市場規模：地域別 - 北米の多血小板血漿（PRP）市場規模 アメリカの多血小板血漿（PRP）市場規模 カナダの多血小板血漿（PRP）市場規模 メキシコの多血小板血漿（PRP）市場規模 … - ヨーロッパの多血小板血漿（PRP）市場規模 ドイツの多血小板血漿（PRP）市場規模 イギリスの多血小板血漿（PRP）市場規模 フランスの多血小板血漿（PRP）市場規模 … - アジア太平洋の多血小板血漿（PRP）市場規模 中国の多血小板血漿（PRP）市場規模 日本の多血小板血漿（PRP）市場規模 インドの多血小板血漿（PRP）市場規模 … - 南米/中東の多血小板血漿（PRP）市場規模 南アフリカの多血小板血漿（PRP）市場規模 ブラジルの多血小板血漿（PRP）市場規模 アルゼンチンの多血小板血漿（PRP）市場規模 … ・競争状況 ・市場機会・将来動向 |
The platelet-rich plasma market is expected to register a CAGR of 12.4% during the forecast period (2022-2027).
The current COVID-19 pandemic further helped expand the market due to the lack of antiviral therapies and the fact that plasma therapy comes under an emergency treatment method. One of the benefits of platelet-rich plasma is that it can be used for pain relief during COVID-19. This technique, which has been used to avoid surgery, is also effective in providing short-term pain relief in patients waiting to be cleared for surgical intervention and not wanting to be further postponed by the adverse effects of steroids.
The key factors that are augmenting the market’s growth include rising incidences of sports injuries, an increasing number of cosmetic and surgical procedures, and the growing use of platelet-rich plasma in various therapeutic areas. As per the American Society of Plastic Surgeons (ASPS), approximately 18.1 million cosmetic procedures were performed in 2019 in the United States. It was observed that the number of procedures increased over the last five years, and the preference of people for minimally invasive cosmetic surgery across the United States has increased. Procedures like liposuction and facelifts are growing in popularity.
Platelet-rich plasma (PRP) contains at least seven growth factors. It can be used for various treatments, such as chronic tendon injuries, acute ligament and muscle injuries, surgery, knee arthritis, fractures, and pain. In orthopedics, the use of PRP is expected to increase over the forecast period. PRP is increasingly being used in the treatment of acute sports injuries, such as muscle injuries. The popularity of PRP is on the rise, but its true effectiveness is yet to be fully established. Thus, the PRP is widely used in surgery to repair torn knee ligaments, such as the anterior cruciate ligament (ACL). The PRP facilitates the fast healing of the tissue after surgical procedures.
Several research studies are currently being conducted to evaluate the effectiveness of PRP in other treatment areas, such as in the case of herniated disc and hair loss. The use of PRP has grown widely in different therapeutic areas due to the increasing availability and ability to enable faster healing. Additionally, this treatment can reduce the economic costs of standard medical procedures, although it cannot replace certain important conventional therapies.
Platelet Rich Plasma Market Trends
The Orthopedics Segment is Expected to Hold the Largest Market Share
The US Food and Drug Administration witnessed a tremendous rise in the number of clinical trials in the past few months regarding the use of plasma-rich proteins in treating the coronavirus. Various manufacturers operating in the plasma therapy market are investing heavily in R&D and clinical trials in the hope of coming up with an antivirus to fight the coronavirus.
According to the article published in the Lancet Journal in 2020, arthritis is the leading cause of disability among adults. Moreover, knee osteoarthritis has a high prevalence among all osteoarthritis. In 2020, there were approximately 654 million people in the world who had knee OA (age 40 and up). Knee osteoarthritis was found to be prevalent in people aged 20 and up at a rate of 203 per 10,000 person-years.
Despite not being considered the standard practice, a growing number of people are opting for PRP injections to treat an expanding list of orthopedic conditions, including osteoarthritis. It is most commonly used for knee osteoarthritis but may be used on other joints as well. While treating osteoarthritis with platelet-rich plasma, a doctor injects PRP directly into the affected joint to reduce pain, improve joint function, and slow, halt, or even repair damage to the cartilage. In such cases, platelet-rich plasma is derived from a sample of the patient’s blood.
Thus, platelet-rich plasma therapy is witnessing a significant rise in its popularity and acceptance for treating arthritis since it inhibits inflammation, reduces the rate of progression of osteoarthritis, stimulates the formation of new cartilage, and increases the production of natural lubricating joint fluid, in turn, easing painful joint friction. Moreover, it contains proteins that alter a patient’s pain receptors, hence reducing pain sensation. Hence, the factors mentioned above are expected to fuel the growth of the orthopedics segment.
North America Dominates the Market and is Expected to show a Similar Trend over the Forecast Period
The market growth in the United States can be attributed to several factors, including the rise in the prevalence of several disorders, such as arthritis, well-established healthcare infrastructure, better regulatory framework, and government support. As per a survey conducted by the Centers for Disease Control and Prevention (CDC) in 2020, in the United States, one out of every four adults suffered from arthritis, and an estimated 78 million adults are expected to suffer from the disease by 2040.
Moreover, in the region, due to the growing aging population, the prevalence of doctor-diagnosed arthritis is expected to rise significantly over the forecast period. Osteoarthritis is the most prevalent type of arthritis, and it affects about 31 million Americans every year.
PRP is also one of the techniques that are very commonly used in cosmetic procedures. Platelet-rich plasma treatment is the latest anti-aging procedure for enhancing facial shape and adding volume. Hence, all these factors mentioned above are expected to contribute to the growth of the platelet-rich plasma market in the region.
Platelet Rich Plasma Market Competitor Analysis
The market is moderately competitive with few key players. Some key market players include Arthrex Inc., Cambryn Biologics LLC, China Biologic Products Inc., DePuy Synthes, Dr. PRP USA LLC, EmCyte Corporation, Glofinn Oy, T-Biotechnology, Terumo BCT Inc., and Zimmer Biomet. With the advancement in technology, new players are expected to enter the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Sports Injuries
4.2.2 Increasing Number of Cosmetic and Surgical Procedures
4.2.3 Growing use of Platelet-rich Plasma in Various Therapeutic Areas
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 High Prices of Plasma Therapy
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Pure PRP
5.1.2 Leukocyte-rich PRP
5.1.3 Leukocyte-rich Fibrin
5.1.4 Other Types
5.2 By Application
5.2.1 Orthopedics
5.2.2 Cosmetic Surgery and Dermatology
5.2.3 Neurology
5.2.4 Cardiology
5.2.5 Ophthalmology
5.2.6 Other Applications
5.3 By End User
5.3.1 Hospitals and Clinics
5.3.2 Research Institutes
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Arthrex Inc.
6.1.2 Isto Biologics
6.1.3 Vertical Spine LLC
6.1.4 DePuy Synthes
6.1.5 Dr. PRP USA LLC
6.1.6 EmCyte Corporation
6.1.7 Glofinn Oy
6.1.8 T-Biotechnology
6.1.9 Terumo BCT Inc.
6.1.10 Zimmer Biomet
6.1.11 Harvest Technologies Corporation
6.1.12 ISTO Biologics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS